NasdaqGS - Delayed Quote • USD
Black Diamond Therapeutics, Inc. (BDTX)
At close: April 25 at 4:00 PM EDT
Pre-Market: 8:00 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 5 |
| Avg. Estimate | -0.43 | -0.43 | -1.71 | -1.79 |
| Low Estimate | -0.52 | -0.52 | -1.87 | -2.01 |
| High Estimate | -0.4 | -0.35 | -1.49 | -1.58 |
| Year Ago EPS | -0.57 | -0.52 | -1.88 | -1.71 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.61 | -0.54 | -0.49 | -0.47 |
| EPS Actual | -0.57 | -0.52 | -0.45 | -0.34 |
| Difference | 0.04 | 0.02 | 0.04 | 0.13 |
| Surprise % | 6.60% | 3.70% | 8.20% | 27.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.43 | -0.43 | -1.71 | -1.79 |
| 7 Days Ago | -0.43 | -0.43 | -1.71 | -1.79 |
| 30 Days Ago | -0.43 | -0.44 | -1.73 | -1.94 |
| 60 Days Ago | -0.52 | -0.53 | -2.09 | -2.21 |
| 90 Days Ago | -0.52 | -0.53 | -2.09 | -2.21 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BDTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 24.60% | -- | -- | 2.60% |
| Next Qtr. | 17.30% | -- | -- | 13.40% |
| Current Year | 9.00% | -- | -- | 5.20% |
| Next Year | -4.70% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Wedbush: Outperform to Outperform | 4/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/18/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 3/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/22/2023 |
| Reiterates | Wedbush: Outperform to Outperform | 9/12/2023 |
| Initiated | Piper Sandler: Overweight | 7/14/2023 |
Related Tickers
ALEC Alector, Inc.
4.8100
-8.38%
CGEM Cullinan Therapeutics, Inc.
19.25
+1.91%
STOK Stoke Therapeutics, Inc.
11.69
+0.26%
NKTX Nkarta, Inc.
6.82
-4.88%
IGMS IGM Biosciences, Inc.
7.65
-3.89%
PASG Passage Bio, Inc.
1.2200
-1.61%
GOSS Gossamer Bio, Inc.
0.6700
-5.41%
BCEL Atreca, Inc.
0.0855
+0.59%
CABA Cabaletta Bio, Inc.
12.18
-6.02%
ADCT ADC Therapeutics SA
4.4400
-7.11%